Ticker: ANVS

Snapshot - Annovis Bio, Inc. (NYSE: ANVS) Quick take: management is advancing a pivotal Phase 3 Alzheimer's trial while burning cash. A successful February 2025 equity raise temporarily rebuilt the balance sheet, but the company still discloses substantial doubt about its ability to continue as a...

Company Overview: Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson's disease (PD) through its lead product candidate, Buntanetap. Recent Developments: Annovis ...